Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study
Status:
Recruiting
Trial end date:
2020-07-25
Target enrollment:
Participant gender:
Summary
At present, there are no specific treatments for COVID-19. WHO recommends four treatments for
COVID 19 with drugs i.eRemdesivir, Lopinavir/ ritonavir, Lopinavir/ ritonavir with interferon
beta -1a, and chloroquine or hydroxychloroquine. Currently, there are several ongoing
clinical trials evaluating potential treatments. Recently, LeonCaly reported that Ivermectin,
an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in
vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to
Vero-hSLAM cells 2 hours post infection with SARSCoV-2 able to effect about 5000-fold
reduction in viral RNA at 48 h. Ivermectin therefore warrant further investigation for
possible benefits in humans. The study rationale is to understand the effect of the drug on
eradication of virus.